Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed 6/11/2019) Moxifloxacin 400 mg Film-coated Tablets
Section 19A approved medicine
(Approval lapsed 6/11/2019) Moxifloxacin 400 mg Film-coated Tablets
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 516
Phone
1800 181 060
Approved until
Status
Lapsed
Medicines in short supply/unavailable
AVELOX moxifloxacin 400 mg (as hydrochloride) tablet blister pack - ARTG 75766
Indication(s)
For the treatment of adults with infections caused by susceptible organisms in the conditions:
- Acute bacterial sinusitis
- Community acquired pneumonia
- Acute exacerbations of chronic bronchitis
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with Avelox may be initiated, in some conditions, before results of these tests are known. Once results become available, therapy should be continued with the most appropriate antibiotic therapy.
Consideration should be given to available official guidance on the appropriate use of antibacterial agents.